Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib.
Yuan ChengQing YuYan XiongCuiyan GuoLigong NiePublished in: Thoracic cancer (2021)
Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertinib due to elevated mesenchymal epithelial transition (MET) copy number amplification. However, early-onset interstitial pneumonitis occurred within two days.
Keyphrases
- advanced non small cell lung cancer
- early onset
- copy number
- epidermal growth factor receptor
- late onset
- mitochondrial dna
- case report
- tyrosine kinase
- interstitial lung disease
- bone marrow
- stem cells
- dna methylation
- small cell lung cancer
- rheumatoid arthritis
- gene expression
- combination therapy
- replacement therapy
- idiopathic pulmonary fibrosis
- smoking cessation